492 results match your criteria renca


Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model.

Biol Open 2021 Apr 20;10(4). Epub 2021 Apr 20.

Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea.

The incidence of renal cell carcinoma (RCC) is high, and its outcomes remain poor. Mortality is attributable largely to metastatic disease and a dearth of effective therapeutic interventions. The lungs are the most common metastatic site. Read More

View Article and Full-Text PDF

[The threat of climate change on population health and the urgent need to act].

Rev Med Chil 2020 Nov;148(11):1652-1658

Escuela de Salud Pública, Universidad de Chile, Santiago, Chile.

Climate change is associated with negative health outcomes, such as cardiovascular and respiratory diseases. This article analyses the threat of climate change on population health and the urgent need to implement measures to avoid this damage. Heat vulnerability, heatwave exposures, and wildfire exposure to forest fires have increased in Chile. Read More

View Article and Full-Text PDF
November 2020

Absent in melanoma 2-mediating M1 macrophages facilitate tumor rejection in renal carcinoma.

Transl Oncol 2021 Apr 22;14(4):101018. Epub 2021 Jan 22.

Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China; Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China. Electronic address:

Absent in melanoma 2 (AIM2) as an immune regulator for the regulation of tumor-associated macrophages (TAMs) function is unclear in tumor development. Here, the AIM2 function was investigated in TAMs-mediated malignant behaviors of renal carcinoma. The correlation analysis result showed that the AIM2 expression in TAMs was negatively correlated with the percentages of M2-like polarization phenotype in human or murine renal cancer specimens. Read More

View Article and Full-Text PDF

Solving the bin location-allocation problem for household and recycle waste generated in the commune of Renca in Santiago, Chile.

Waste Manag Res 2021 Jan 20:734242X20986610. Epub 2021 Jan 20.

School of Industrial Engineering, Pontificia Universidad Católica de Valparaíso, Valparaiso, Chile.

In the commune of Renca in Santiago, Chile, the household waste is currently collected on the kerbside and then thrown in the rear of a compactor truck. This system becomes inefficient when not all citizens are always serviced, yielding high overall collection costs and negative impacts on the environment and the society. Recently, recyclable waste collection sites have been situated throughout the commune, which need to be examined with respect to population coverage and average travel distances to these sites. Read More

View Article and Full-Text PDF
January 2021

A framework for automated time-resolved analysis of cell colony growth after irradiation.

Phys Med Biol 2021 Jan 29;66(3):035017. Epub 2021 Jan 29.

Department of Radiation Oncology and Radiation Therapy, University Hospital Heidelberg, Germany.

Understanding dose-dependent survival of irradiated cells is a pivotal goal in radiotherapy and radiobiology. To this end, the clonogenic assay is the standard in vitro method, classifying colonies into either clonogenic or non-clonogenic based on a size threshold at a fixed time. Here we developed a methodological framework for the automated analysis of time course live-cell image data to examine in detail the growth dynamics of large numbers of colonies that occur during such an experiment. Read More

View Article and Full-Text PDF
January 2021

Inducing regulated necrosis and shifting macrophage polarization with anti-EMMPRIN antibody (161-pAb) and complement factors.

J Leukoc Biol 2020 Nov 17. Epub 2020 Nov 17.

Immunotherapy Laboratory, Carmel Medical Center, Haifa, Israel.

Treatment of solid tumors is often hindered by an immunosuppressive tumor microenvironment (TME) that prevents effector immune cells from eradicating tumor cells and promotes tumor progression, angiogenesis, and metastasis. Therefore, targeting components of the TME to restore the ability of immune cells to drive anti-tumoral responses has become an important goal. One option is to induce an immunogenic cell death (ICD) of tumor cells that would trigger an adaptive anti-tumoral immune response. Read More

View Article and Full-Text PDF
November 2020

Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression.

ACS Omega 2020 Nov 20;5(43):28273-28284. Epub 2020 Oct 20.

Department of Genetics and Bioengineering, Yeditepe University, Istanbul 34755, Turkey.

Tissue transglutaminase (TG2) is a multifunctional protein that can act as a cross-linking enzyme, GTPase/ATPase, protein kinase, and protein disulfide isomerase. TG2 is involved in cell adhesion, migration, invasion, and growth, as well as epithelial-mesenchymal transition (EMT). Our previous findings indicate that the increased expression of TG2 in renal cell carcinoma (RCC) results in tumor metastasis with a significant decrease in disease- and cancer-specific survival outcome. Read More

View Article and Full-Text PDF
November 2020

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.

Clin Cancer Res 2021 Jan 4;27(2):608-621. Epub 2020 Nov 4.

Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.

Purpose: Intratumoral immunosuppression mediated by myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) represents a potential mechanism of immune checkpoint inhibitor (ICI) resistance in solid tumors. By promoting TAM and MDSC infiltration, IL1β may drive adaptive and innate immune resistance in renal cell carcinoma (RCC) and in other tumor types.

Experimental Design: Using the RENCA model of RCC, we evaluated clinically relevant combinations of anti-IL1β plus either anti-PD-1 or the multitargeted tyrosine kinase inhibitor (TKI), cabozantinib. Read More

View Article and Full-Text PDF
January 2021

Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models.

Sci Rep 2020 10 15;10(1):17464. Epub 2020 Oct 15.

Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

In this study we undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor (ICI) anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate cancer derived from C57BL/6 mice), MBT-2 (bladder cancer derived from C3H mice) and Renca (kidney cancer derived from BALB/c mice) were used in this study. The highest coxsackie and adenovirus receptor (CAR) mRNA expression was observed in TRAMP-C2 cells, followed by Renca and then MBT-2 cells. Read More

View Article and Full-Text PDF
October 2020

Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors.

ACS Nano 2020 10 25;14(10):13343-13366. Epub 2020 Sep 25.

Division of NanoMedicine, Department of Medicine, David Geffen School of Medicine University of California, Los Angeles, California 90095, United States.

We developed a custom-designed liposome carrier for codelivery of a potent immunogenic cell death (ICD) stimulus plus an inhibitor of the indoleamine 2,3-dioxygenase (IDO-1) pathway to establish a chemo-immunotherapy approach for solid tumors in syngeneic mice. The carrier was constructed by remote import of the anthraquinone chemotherapeutic agent, mitoxantrone (MTO), into the liposomes, which were further endowed with a cholesterol-conjugated indoximod (IND) prodrug in the lipid bilayer. For proof-of-principle testing, we used IV injection of the MTO/IND liposome in a CT26 colon cancer model to demonstrate the generation of a robust immune response, characterized by the appearance of ICD markers (CRT and HMGB-1) as well as evidence of cytotoxic cancer cell death, mediated by perforin and granzyme B. Read More

View Article and Full-Text PDF
October 2020

Network design of a household waste collection system: A case study of the commune of Renca in Santiago, Chile.

Waste Manag 2020 Oct 14;116:179-189. Epub 2020 Aug 14.

Department of Engineering Sciences, Universidad Andres Bello, Quillota 980, Viña del Mar, Chile. Electronic address:

This study proposes a design of a household waste collection system based on a two-stage procedure. First, the bin location-allocation problem is solved by selecting collection sites from a set of potential sites, and determining the type and number of bins at each selected collection site. Second, bin-to-bin waste collection routes are obtained for a fleet of homogeneous vehicles that are restricted by either work shift duration or vehicle capacity. Read More

View Article and Full-Text PDF
October 2020

Assessment of RBE-Weighted Dose Models for Carbon Ion Therapy Toward Modernization of Clinical Practice at HIT: In Vitro, in Vivo, and in Patients.

Int J Radiat Oncol Biol Phys 2020 11 3;108(3):779-791. Epub 2020 Jun 3.

Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; National Centre of Oncological Hadrontherapy, Medical Physics, Pavia, Italy; Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. Electronic address:

Purpose: Present-day treatment planning in carbon ion therapy is conducted with assumptions for a limited number of tissue types and models for effective dose. Here, we comprehensively assess relative biological effectiveness (RBE) in carbon ion therapy and associated models toward the modernization of current clinical practice in effective dose calculation.

Methods: Using 2 human (A549, H460) and 2 mouse (B16, Renca) tumor cell lines, clonogenic cell survival assay was performed for examination of changes in RBE along the full range of clinical-like spread-out Bragg peak (SOBP) fields. Read More

View Article and Full-Text PDF
November 2020

Impact of Extracellular Matrix Components to Renal Cell Carcinoma Behavior.

Front Oncol 2020 28;10:625. Epub 2020 Apr 28.

Université de Bordeaux, Bordeaux, France.

Renal cell carcinoma (RCC) represents the main renal tumors and are highly metastatic. They are heterogeneous tumors and are subdivided in 12 different subtypes where clear cell RCC (ccRCC) represents the main subtype. Tumor extracellular matrix (ECM) is composed, in RCC, mainly of different fibrillar collagens, fibronectin, and components of the basement membrane such as laminin, collagen IV, and heparan sulfate proteoglycan. Read More

View Article and Full-Text PDF

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.

Nat Commun 2020 05 1;11(1):2135. Epub 2020 May 1.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

A non-immunogenic tumor microenvironment (TME) is a significant barrier to immune checkpoint blockade (ICB) response. The impact of Polybromo-1 (PBRM1) on TME and response to ICB in renal cell carcinoma (RCC) remains to be resolved. Here we show that PBRM1/Pbrm1 deficiency reduces the binding of brahma-related gene 1 (BRG1) to the IFNγ receptor 2 (Ifngr2) promoter, decreasing STAT1 phosphorylation and the subsequent expression of IFNγ target genes. Read More

View Article and Full-Text PDF

Evaluation of anti-cancer potency of silibinin on murine renal carcinoma RenCa cells in an animal model with an intact immune system.

Anticancer Drugs 2020 09;31(8):785-791

Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University.

Silibinin is a flavonoid extract isolated from milk thistle and has been proved to be a promising chemotherapeutic drug for cancer. However, most of those studies were performed on the human cancer cells, where the effects of silibinin could only be observed on an animal model with a deficient immune system. RenCa cells were isolated from a murine spontaneous renal cell carcinoma, which resembles many features of human renal cell carcinoma, and have been used to establish animal models with a sound immune response. Read More

View Article and Full-Text PDF
September 2020

Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood.

Invest New Drugs 2020 10 20;38(5):1618-1626. Epub 2020 Mar 20.

US Biotest, Inc., 231 Bonetti Drive, Suite 240, San Luis Obispo, CA, 93401, USA.

Administration of chemotherapeutics as direct injections into tumors offers increased anti-tumor activity and reduced systemic toxicity. In this study, the Renca syngeneic murine xenograft model of renal cancer was used to evaluate the effects of intratumoral (IT) submicron particle docetaxel (NanoDoce®) on tumor growth and immunomodulation. Tumor volume (TV) was compared to controls, including intravenous (IV) chemotherapy. Read More

View Article and Full-Text PDF
October 2020

Cadmium and Lead Decrease Cell-Cell Aggregation and Increase Migration and Invasion in Renca Mouse Renal Cell Carcinoma Cells.

Int J Mol Sci 2019 Dec 14;20(24). Epub 2019 Dec 14.

Department of Medical Pharmacology and Physiology, School of Medicine, University of Missouri, Columbia, MO 65212, USA.

Metastatic renal cell carcinoma (RCC) remains an important clinical issue; the 5-year survival rate of patients with metastasis is approximately 12%, while it is 93% in those with localized disease. There is evidence that blood cadmium and lead levels are elevated in RCC. The current studies were designed to assess the impact of cadmium and lead on the progression of RCC. Read More

View Article and Full-Text PDF
December 2019

Silencing of nuclear factor kappa b 1 gene expression inhibits colony formation, cell migration and invasion via the downregulation of interleukin 1 beta and matrix metallopeptidase 9 in renal cell carcinoma.

Mol Biol Rep 2020 Feb 10;47(2):1143-1151. Epub 2019 Dec 10.

Department of Biotechnology, IPEN-CNEN/SP, 2242 Av. Lineu Prestes, Cidade Universitária, Butantã, São Paulo, 05508-000, Brazil.

Renal cell carcinoma (RCC) is a highly deadly urological tumor due to its high metastatic incidence and its notorious chemoresistance. The nuclear transcription factor kappa B (NF-κB) family has been associated with apoptosis resistance and cellular invasion in RCC. The purpose of this study was to evaluate the impact of NF-κB1 gene silencing on the colony formation, cell migration and invasion abilities of the RCC cell line. Read More

View Article and Full-Text PDF
February 2020

Tissue-specific tumor microenvironments influence responses to immunotherapies.

Clin Transl Immunology 2019 21;8(11):e1094. Epub 2019 Nov 21.

Cancer Immunology Program Peter MacCallum Cancer Centre Melbourne VIC Australia.

Objectives: Investigation of variable response rates to cancer immunotherapies has exposed the immunosuppressive tumor microenvironment (TME) as a limiting factor of therapeutic efficacy. A determinant of TME composition is the tumor location, and clinical data have revealed associations between certain metastatic sites and reduced responses. Preclinical models to study tissue-specific TMEs have eliminated genetic heterogeneity, but have investigated models with limited clinical relevance. Read More

View Article and Full-Text PDF
November 2019

Animal models of spontaneous renal carcinoma: A possible rebirth?

Urol Oncol 2020 04 21;38(4):174-183. Epub 2019 Nov 21.

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy.

Introduction and Objectives The animal models for renal carcinogenesis have allowed researchers to better understand the physiopathological, genetic, molecular, and immunological mechanisms underlying the development of human renal cancers from the induction of precancerous lesions to the metastatic process. Our study aimed to review and discuss the characteristics of all the spontaneous animal models of renal carcinogenesis described in scientific literature to date and see how they could address future challenges in the field of personalized medicine. Methods and Materials We reviewed all the papers on PubMed which focus on spontaneous animal models of renal carcinogenesis. Read More

View Article and Full-Text PDF

The immunogenic potential of bacterial flagella for Salmonella-mediated tumor therapy.

Int J Cancer 2020 07 7;147(2):448-460. Epub 2020 Jan 7.

Infection Biology of Salmonella, Helmholtz Centre for Infection Research, Braunschweig, Germany.

Genetically engineered Salmonella Typhimurium are potent vectors for prophylactic and therapeutic measures against pathogens as well as cancer. This is based on the potent adjuvanticity that supports strong immune responses. The physiology of Salmonella is well understood. Read More

View Article and Full-Text PDF

CD4 and CD8a PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.

Theranostics 2019 18;9(26):8221-8238. Epub 2019 Oct 18.

Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Dept. of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Denmark.

Predicting the outcome of immunotherapy is essential for efficient treatment. The recent clinical success of immunotherapy is increasingly changing the paradigm of cancer treatment. Accordingly, the development of immune-based agents is accelerating and the number of agents in the global immuno-oncology pipeline has grown 60-70% over the past year. Read More

View Article and Full-Text PDF

Mercury and methylmercury levels in soils associated with coal-fired power plants in central-northern Chile.

Chemosphere 2019 Dec 7;237:124535. Epub 2019 Aug 7.

Laboratorio de Química Analítica y Ambiental, Instituto de Química, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.

Mercury pollution is a worldwide problem, and is associated with a number of natural and anthropogenic processes. The present work, conducted in Chile, a country that has traditionally depended heavily on fossil fuels for power generation, examines total mercury (THg) and monomethylmercury (MMHg) concentrations in soils across different sites exposed to coal fired power plant emissions. Samples from four selected (Renca, Laguna Verde, Las Ventanas, Huasco) and 1 control (Quintay) sites were analyzed using cold vapour and fluorescence spectroscopy (CV-AFS) for THg determination and chromatographic separation with atomic fluorescence detection (DI-GC-AFS) was followed for speciation analysis. Read More

View Article and Full-Text PDF
December 2019

CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.

Melanoma Res 2020 02;30(1):14-25

Beth Israel Deaconess Medical Center, Boston.

To determine whether blockade of the chemokine receptor CXCR4 might alter the tumor microenvironment and inhibit tumor growth, we tested the efficacy of the CXCR4 antagonist X4-136 as a single agent and in combination with various immune checkpoint inhibitors in the syngeneic murine melanoma model B16-OVA. We also tested its activity alone and in combination with axitinib in the renal cancer model Renca. We found that X4-136 exhibited potent single agent antitumor activity in the B16-OVA model that was additive to that of an anti-PDL1 antibody. Read More

View Article and Full-Text PDF
February 2020

Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.

Anticancer Res 2019 Sep;39(9):4737-4742

Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

Background/aim: There are several unresolved issues regarding the combined treatment with an immune checkpoint inhibitor and anti-angiogenic agent for renal cell carcinoma (RCC) patients. The purpose of this study was to address the inhibitory effects of programmed death-ligand 1 (PD-L1) expression on growth and sensitivity to sunitinib in the mouse RCC RenCa model.

Materials And Methods: We established RenCa/sh-PD-L1 by transfecting RenCa cells with a plasmid carrying a short hairpin RNA targeted against PD-L1. Read More

View Article and Full-Text PDF
September 2019

MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma.

J Cell Biochem 2020 02 9;121(2):1504-1513. Epub 2019 Sep 9.

College of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, China.

MicroRNA-96 (miR-96) is a vertebrate conserved microRNA which plays important roles in various cancers including renal cell carcinoma (RCC). However, its function and mechanism in RCC are still unclear. In this study, miR-96 was found to be downregulated in RCC based on The Cancer Genome Atlas datasets analyses, and its target genes, which predicted by TargetScan, were investigated. Read More

View Article and Full-Text PDF
February 2020

CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect.

Oncol Rep 2019 Aug 20;42(2):866-879. Epub 2019 Jun 20.

Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China.

A satisfactory cure rate for renal cell carcinoma (RCC) is difficult to achieve through traditional immunotherapy. RCC has a relatively high spontaneous regression rate due to tumor immune escape. However, tumor‑derived exosomes (TEXs), which effectively carry tumor‑associated antigens (TAAs) and trigger stronger antigen‑specific tumor immunity against autologous tumors than against other tumors, have been widely viewed as attractive potential vaccines for tumor treatment, although improvements are needed. Read More

View Article and Full-Text PDF

An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.

Hum Gene Ther 2019 09 1;30(9):1117-1132. Epub 2019 Jul 1.

Gene Therapy Program, Department of Medicine, NorthShore Research Institute, an Affiliate of the University of Chicago, Evanston, Illinois.

In an effort to develop a new therapy for cancer and to improve antiprogrammed death inhibitor-1 (anti-PD-1) and anticytotoxic T lymphocyte-associated protein (anti-CTLA-4) responses, we have created a telomerase reverse transcriptase promoter-regulated oncolytic adenovirus rAd.sT containing a soluble transforming growth factor receptor II fused with human IgG Fc fragment (sTGFβRIIFc) gene. Infection of breast and renal tumor cells with rAd. Read More

View Article and Full-Text PDF
September 2019

Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma and .

J Cancer 2019 23;10(6):1466-1478. Epub 2019 Feb 23.

Yeditepe University, Faculty of Engineering, Department of Genetics and Bioengineering, Kayisdagi Cad., 34755, Istanbul, Turkey.

Renal cell carcinoma (RCC) is the predominant type of kidney cancer. Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients. The clinical limitation confronted during everolimus therapy is the onset of drug resistance that decreases the efficacy of the drug. Read More

View Article and Full-Text PDF
February 2019

Expression profiling of plac1 in murine cancer cell lines

Exp Oncol 2019 03;41(1):7-13

Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran 14155/6446, Iran

Aim: Placenta-specific 1 (PLAC1) is among recently-discovered placental antigens which exerts fundamental role in placental function and development. Increasing body of literature shows that PLAC1 is frequently activated and expressed in a wide variety of human cancers and promote cancer progression. However, no data is available regarding the expression of mouse orthologue, plac1, in murine cancer cell lines. Read More

View Article and Full-Text PDF